Advocacy intelligence hub — real-time data for patient organizations
Beijing Kangchuanglian Biopharmaceutical Technology Research Co., Ltd — PHASE1, PHASE2
Shanghai EpimAb Biotherapeutics Co., Ltd. — PHASE1, PHASE2
AvenCell Therapeutics, Inc.
Peking University People's Hospital — EARLY_PHASE1
University of Washington — PHASE2
Universität Münster — PHASE2
National Cancer Institute (NCI) — PHASE2
Navy General Hospital, Beijing — PHASE2
Beijing GoBroad Hospital
Children's Cancer Group, China — PHASE2, PHASE3
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Zevalin
(ibritumomab tiuxetan)Orphan drugstandardAcrotech Biopharma LLC
12.1 Mechanism of Action Ibritumomab tiuxetan binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35). Th...
Mehdi Hamadani, MD
Medical College of Wisconsin
Barbara Pro, MD, M.D
Columbia University
📍 NEW YORK, NY
Ajay Gopal
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA
Birgit Burkhardt, Prof. Dr. Dr.
University Hospital Muenster, Klinik für Kinder- und Jugendmedizin - Pädiatrische Hämatologie und Onkologie
Raphael E Steiner, MD
University of Texas MD Anderson Cancer Center LAO
📍 NEW YORK, NY
Lorenz Thurner, Professor
Saarland University, Saarland University Hospital
View all Aggressive B-cell non-Hodgkin lymphoma specialists →